Sotorasib (LUMAKRAS<sup>™</sup>) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatme...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!